Donanemab and lecanemab have been shown to delay progression from mild to moderate Alzheimer's by up to six months but are ...

NHS watchdog to review evidence on two pioneering Alzheimer’s drugs - Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed their ben ...

New treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and motor neuron disease (MND) could be unlocked thanks to microscopic medicines developed by researchers at the University ...

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AßOs) for the treatment of Alzheimer’s disease ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease.

The groups are calling for genotype-informed prevention and treatment strategies, APOE stratification in clinical trials, and related public policies.

A major new study finds people with type 1 diabetes face nearly three times the dementia risk. But lifestyle changes and new treatments offer real hope.

The need for neurological care is especially acute in South Carolina, which has struggled to deliver timely, top-notch brain ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

Alzheimer’s disease affects millions of people around the world and is one of the leading causes of memory loss and cognitive ...

Smith Could a simple blood test predict your risk of getting dementia years, or even decades, before you experience memory ...

Now, with the passing of House Bill 565, also known as Jill’s Law, all Mississippians will have access to biomarker testing ...